iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Convertible Promissory Note Receivable

Convertible Promissory Note Receivable	3 Months Ended
Sep. 30, 2022
Convertible Promissory Note Receivable [Abstract]
Convertible Promissory Note Receivable	7. Convertible Promissory Note Receivable On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (“Safi”). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi’s common stock (as defined). Principal and accrued interest mature on October 1, 2023. For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September 30, 2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively.

Convertible Promissory Note Receivable

3 Months Ended

Sep. 30, 2022

Convertible Promissory Note Receivable [Abstract]

Convertible Promissory Note Receivable

7. Convertible Promissory Note Receivable

On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (“Safi”). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi’s common stock (as defined). Principal and accrued interest mature on October 1, 2023. For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September 30, 2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively.